Complications and Treatments in Adult X-Linked Hypophosphatemia
X-linked hypophosphatemia (XLH) is a rare inherited disorder involving elevated levels of fibroblast growth factor (FGF) 23, and is caused by loss-of-function mutations in the <i>PHEX</i> gene. FGF23 induces renal phosphate wasting and suppresses the activation of vitamin D, resulting in...
Main Authors: | Yasuo Imanishi, Tetsuo Shoji, Masanori Emoto |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Endocrines |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-396X/3/3/47 |
Similar Items
-
Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
by: Aaron Schindeler, et al.
Published: (2020-05-01) -
Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia
by: Silvia Martín Ramos, et al.
Published: (2020-02-01) -
Different Efficacy of Burosumab on Physical Performance and Serum Phosphate in Adult Patients with X-Linked Hyphophosphatemic Rickets during the First Six-Month of Treatment
by: Teresa Arcidiacono, et al.
Published: (2023-04-01) -
The Variant p.Ala84Pro Is Causative of X-Linked Hypophosphatemic Rickets: Possible Relationship with Burosumab Swinging Response in Adults
by: Maria Carmela Zagari, et al.
Published: (2022-12-01) -
Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries
by: M. Zulf Mughal, et al.
Published: (2023-01-01)